Endocare to list on Nasdaq
This article was originally published in Clinica
Executive Summary
Endocare, a US company marketing cryosurgical therapy devices for prostatic hyperplasia and cancer, is to get a listing on the Nasdaq stock market. The Irvine, California-based company is also developing cryosurgical technologies for treating tumours in other organs, including the kidney, breast and liver.